Skip to content

Study · In vitro (cells) · 2022

6 results

Nicotinamide mononucleotide increases cell viability and restores tight junctions in high-glucose-treated human corneal epithelial cells via the SIRT1/Nrf2/HO-1 pathway.

Pu Q, Guo XX, Hu JJ, Li AL, Li GG, Li XY

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2 Feb 2022Cited by 41 (Europe PMC)

PMID35123232 (opens in a new tab)DOI10.1016/j.biopha.2022.112659 (opens in a new tab)PepBankPUB-35123232
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In high-glucose-treated human corneal epithelial cells, NMN increased viability.

    In plain wordsIn cells exposed to high glucose, NMN increased viability.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseCell viability
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Cell viability and death · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN increased cell viability by reducing cell damage, reducing apoptosis, increasing cell migration, and restoring tight junctions in HG-treated HCECs.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.
  2. 02LabIn vitro (cells)Efficacy outcome

    In high-glucose-treated human corneal epithelial cells, NMN reduced cell damage.

    In plain wordsIn cells exposed to high glucose, NMN reduced cell damage.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseCell damage
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Cell viability and death · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN increased cell viability by reducing cell damage, reducing apoptosis, increasing cell migration, and restoring tight junctions in HG-treated HCECs.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.
  3. 03LabIn vitro (cells)Mechanism

    In high-glucose-treated human corneal epithelial cells, NMN reduced apoptosis.

    In plain wordsIn cells exposed to high glucose, NMN reduced programmed cell death.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseApoptosis
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Cell viability and death · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN increased cell viability by reducing cell damage, reducing apoptosis, increasing cell migration, and restoring tight junctions in HG-treated HCECs.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.
  4. 04LabIn vitro (cells)Efficacy outcome

    In high-glucose-treated human corneal epithelial cells, NMN increased cell migration.

    In plain wordsIn cells exposed to high glucose, NMN increased cell migration.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseCell migration
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Wound healing · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN increased cell viability by reducing cell damage, reducing apoptosis, increasing cell migration, and restoring tight junctions in HG-treated HCECs.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.
  5. 05LabIn vitro (cells)Efficacy outcome

    In high-glucose-treated human corneal epithelial cells, NMN restored tight junctions.

    In plain wordsIn cells exposed to high glucose, NMN restored tight junctions.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseTight junction restoration
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    NMN increased cell viability by reducing cell damage, reducing apoptosis, increasing cell migration, and restoring tight junctions in HG-treated HCECs.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.
  6. 06LabIn vitro (cells)Mechanism

    In high-glucose-treated human corneal epithelial cells, expression analyses implicated SIRT1/Nrf2/HO-1 signaling in NMN protection.

    In plain wordsIn cells exposed to high glucose, protein analyses linked NMN protection to the SIRT1/Nrf2/HO-1 pathway.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedSIRT1/Nrf2/HO-1 pathway
    Study

    humann: not reported in source

    High-glucose-treated human corneal epithelial cells
    Outcome group
    Receptor activity and mechanism · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    By analyzing the expressions of SIRT1, Nrf2, HO-1, NMN demonstrated protective effects via the SIRT1/Nrf2/HO-1 pathway.
    1 context sentence
    Summary · context
    We conducted an in-vitro study to examine the effects of NMN treatment on HG-treated HCECs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.